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Abstract 
Background: Crimean-Congo hemorrhagic fever epidemics often occur in areas 
where health services are limited, and result in high case fatality rates. Besides 
intensive care, ribavirin is often recommended. A solid evidence base for the use of 
this drug will help justify assuring access to the drug in areas where epidemics are 
common. 
Methods: We carried out a systematic review of observational and experimental 
studies of people with suspected or confirmed Crimean-Congo hemorrhagic fever 
that included comparisons between patients given ribavirin and those not. We 
extracted data on mortality, hospital stay, and adverse events. Risk of bias was 
assessed using a standard checklist, and data were presented in meta-analytical 
graphs, stratified by study design, and GRADE tables presented. The risk of bias was 
summarised using the GRADE method. 
Results: 21 unique studies, including one randomised controlled trial of ribavirin, 
were included. Quality of the evidence was very low, with a Down and Black median 
score of 4 (maximum possible 33). Ribavirin treatment was not shown to be superior 
to no ribavirin treatment for mortality rate in a single RCT (RR: 1.13, 95%CI: 0.29 to 
4.32, 136 participants, GRADE=low quality evidence); but ribavirin was associated 
with reduced mortality by 44% when compared to no ribavirin treatment in the 
pooled observational studies (RR: 0.56, 95%CI: 0.35 to 0.90, 955 participants; 
GRADE=very low quality evidence). Adverse events were more common with the 
ribavirin patients, but no severe adverse events were reported. No difference in 
length of hospital stay was reported. 
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Conclusions: No clear message of benefit is available from the current data on 
ribavirin as observational data are heavily confounded, and the one trial carried out 
has limited power. However, ribavirin could potentially have benefits in this 
condition and these results clearly indicate a pragmatic, randomised controlled trial 
in the context of good quality supportive care, is urgently needed and ethically 
justified. 
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Background 
Crimean-Congo hemorrhagic fever (CCHF) is a potentially fatal viral disease. The 
CCHF virus is a member of the Nairovirus genus of the Bunyaviridae family. This 
genus includes other species which are pathogens in humans such as the Dugbe virus 
and the Nairobi sheep disease virus [1, 2]. It possesses 3 segments of negative-sense 
RNA [3, 4] and an RNA dependant RNA polymerase packed within a lipid envelope 
which contains 2 viral glycoproteins [Gn and Gc]. This structure is characteristic of 
other members of the Bunyaviridae family. 
 
The virus is transmitted to humans through tick bites or exposure to blood and 
tissues of infected animals. Different domestic and wild animals have been identified 
as a reservoir for this virus, including cattle, sheep, goats, hedgehogs and hares [5-8]. 
Numerous species of ticks can carry the virus, however very few of them have been 
implicated as vectors. The most important tick vector is the Hyalomma spp., as the 
virus was isolated from it and its geographic distribution coincides with that of the 
disease [9]. Another transmission route of the virus in humans is through contact 
with the blood of an infected person during the acute phase of the disease [10]. This 
is especially significant among healthcare workers who may be infected while 
treating CCHF patients during an outbreak [11]. 
 
One of the most important features of the virus is its diverse geographic distribution 
including Africa, Asia, Eastern Europe and the Middle East [12], making it the most 
widespread tick-borne virus infecting humans. Outbreaks have been documented in 
 5 
all these areas since the 1960s, with the most recent cases coming from Iran [13] and 
Turkey [14]. In addition, climatic, environmental and agricultural changes may affect 
the distribution of the tick vector and influence the location and timing of outbreaks.  
 
The pathogenesis of CCHF remains elusive, mainly due to lack of adequate animal 
models and laboratories with the proper bio-safety containment level. Studies in 
human patients reveal endothelial damage resulting from either direct infection of 
the cells or indirect effect of viral and host factors [15, 16]. The clinical features of 
CCHF are divided into four periods - incubation, pre-hemorrhagic, hemorrhagic, and 
convalescence [9]. The incubation period may vary between 2-9 days according to 
the transmission route [10]. This may be followed by a sudden onset of signs such as 
fever, headache, myalgia, arthralgia, abdominal pain and vomiting. Additional signs 
may also appear including sore throat, conjunctivitis, jaundice, photophobia and 
various sensory and mood alterations. In severe cases, hemorrhagic manifestations 
may appear as early as 3-6 days following disease onset. Petechiae and ecchymosis 
of the skin and mucous membranes, as well as gastrointestinal bleeding are the most 
common signs at this stage, while cerebral hemorrhage and liver necrosis reveal a 
more severe manifestation with poorer prognosis [14]. Mortality rates usually range 
between 5-50% [9], although numbers as high as 80% have been reported 
sporadically [6].  
 
Early diagnosis is essential in CCHF cases and is currently possible using first line 
molecular methods for rapid diagnosis such as reverse transcription PCR (RT-PCR) 
and real-time PCR. Serological methods such as ELISA and immunofluorescent assays 
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may also provide a sensitive and specific diagnosis approximately 7 days following 
disease onset. Different cell line cultures and inoculation of the virus into mice may 
be used for virus isolation [14].  
 
Prompt supportive treatment including blood products administration is the major 
current therapeutic option, although several attempts have been made in the past to 
treat patients with immunoglobulins produced from vaccinated horses [9] and with 
serum taken from convalescing CCHF patients [17]. To date, however, no clinical 
trials have been reported testing the latter interventions. More recently, the anti-
viral drug ribavirin - a synthetic purine nucleoside analogue synthesized in 1972 [18] 
- has revealed promising activity against the CCHF virus in vitro [19] and in an animal 
model of mice [20]. Several observational studies suggest efficacy of ribavirin in 
human patients [21-23], while evidence from randomised controlled clinical studies 
is lacking.  
 
As CCHF activity appears to be increasing, particularly in European regions [24, 25], it 
becomes essential to assess the effectiveness of ribavirin treatment. If results 
indicate that treatment with ribavirin is promising, efforts will need to be made to 
ensure its availability in areas of the world where CCHF is present. On the other 
hand, if the evidence is of poor quality and results remain inconclusive, focus will 
need to be targeted on securing better data as well as diminishing harm experienced 
by the patient. At the moment, there appears to be a gap between strongly held 
clinical beliefs and actual provision of ribavirin. 
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Our goal was to appraise and summarise the evidence about benefits and harms of 
ribavirin for treating CCHF in humans. Secondary objectives were to evaluate the 
effects of ribavirin, according to severity of disease and number of days from onset 
of illness that the drug was started, duration of ribavirin treatment, via of 
administration; and to evaluate whether prophylactic use following exposure to 
CCHF virus should be recommended. 
 
Methods   
Inclusion criteria 
Type of studies: Randomised trials (RCTs) or observational studies comparing the 
efficacy of ribavirin with any other intervention or no treatment. Case series were 
limited to the ones with more than 10 cases, and were only summarised 
qualitatively. 
 
Types of participants: Children and adults of any age, with a suspected or confirmed 
diagnosis of CCHF. 
 
Types of interventions: Ribavirin compared to any other intervention or no 
treatment, regardless of via of administration or schedule. 
 
Outcome measures: The primary outcome was the rate of mortality among 
intervention and control groups. Secondary outcomes were: (i) rate of mortality 
among those receiving ribavirin treatment in the first 5 days from the onset of 
symptoms or later than 6 days; (ii) duration of hospital stay; (iii) improvement of 
 8 
disease symptoms; (iv) time to recovery from symptoms; (v) serious adverse events 
that could be fatal or lead to treatment discontinuation; (vi) any reported adverse 
event; and (vii) the development of CCHF after prophylactic use of ribavirin in health 
care workers. 
 
If information was available, all outcomes were categorised according to severity of 
disease, number of days from possible exposure to onset of symptoms, duration of 
treatment, severity of gastrointestinal symptoms, and via of administration. 
 
Search strategy   
We attempted to identify all relevant studies regardless of language or publication 
status (published, unpublished). Search strategies were developed from insertion 
until September 2009 for the following databases: MEDLINE 
(http://www.nlm.nih.gov/databases/databases_medline.html), EMBASE 
(http://www.embase.com/), The Cochrane Library (2009, Issue 3), Current 
Controlled Trials Register, and ISI Citation Indexes at Web of Science (ISI). In addition, 
the internet was searched via general search engines, such as Google Scholar, for 
relevant studies and the reference lists of the included studies were also checked. 
Details of search strategies can be found in the online material (Additional file 1. 
Search Strategy). 
 
Data collection and assessment 
This systematic review followed the Cochrane Collaboration Handbook [26].  
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Two reviewers independently inspected the abstract of each reference identified by 
the search. For potentially relevant articles, or in cases of disagreement, the full 
article was obtained, independently inspected and inclusion criteria were applied. 
Any disagreement was resolved through discussion and the abstract was checked by 
a third reviewer. Justifications for excluding studies from the review were 
documented. 
 
Data extraction forms were developed and piloted independently on a small 
selection of studies varying in quality. Two reviewers independently extracted 
information on study population, setting, details of intervention(s) used and 
outcomes. Data extraction was discussed and decisions documented. Studies were 
identified using the name of the first author and year in which the study was first 
published. Risk of bias was assessed independently by two reviewers using the 
Downs & Black checklist for observational studies [27] and summarized using the 
GRADE methodology [28]. Any disagreements were resolved by consensus.  
 
Statistical analyses  
Statistical analyses were performed using Comprehensive Meta-analysis (version 2). 
Dichotomous data was analysed by calculating the risk ratio (RR) for each study and 
the correspondent 95% confidence intervals. Continuous data was analysed by 
calculating the standardised difference in means (SMD) for each study and the 
correspondent 95% confidence intervals [26]. All analyses were conducted using the 
random-effects model (inverse of variance method), as we combined studies with 
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different methodological design and assumed that the true effect size varied from 
study to study [29]. 
 
Presence of statistical heterogeneity was assessed with the Q-test (considered 
significant for p < 0.10) [30] and quantified using I-squared (I2) [31, 32]. In addition, 
the between-study variance (random effects) was calculated by estimating the 
standard deviation of underlying effects across studies (TAU) [26]. 
 
We planned to conduct subgroup analyses to investigate whether the effects of 
ribavirin differs according to: CCHF severity of symptoms, number of days from onset 
of symptoms to starting the drug, duration of treatment, severity of gastrointestinal 
symptoms and via of administration. Only data on duration of treatment was 
provided in three studies and analysed separately. 
 
Results 
Search results 
We retrieved 1071 references from database and internet site searches. After 
manually removing duplicates, two reviewers independently screened 598 articles, 
and the full report of 106 potentially relevant studies was obtained. Of these, we 
included 21 studies (37 references) and excluded 69 references (Figure 1). The 
primary reasons for excluding studies were as follows: case series with less than 10 
cases reported (n=20), ribavirin was not used to treat CCHF (n=24), not original 
studies (n=13), not about CCHF (n=8) and other reasons (n=4).  
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Ultimately, two randomised trials [33, 34], nine historical control [22, 35-42], one 
case-control [43], two cohort [44, 45], two cross-sectional studies [46, 47] and five 
case-series with more than 10 participants [48-52] were included in the current 
review. Studies were conducted in Iran [22, 34, 35, 46, 47, 49], Pakistan [42, 50, 52], 
Turkey [33, 36-41, 43-45, 48] and Russia [51]. 
 
Study characteristics 
Participants: In one study, participants were children and adolescents with an 
average age of 13.3 (SD=4.6) years [46]; all participants in the other studies were 
adults and the average age ranged from 26 to 54 years old. The percentage of 
females in the studies ranged from 22% to 68%. Eight studies included only 
participants with a confirmed diagnosed of CCHF (confirmed cases by using PCR, 
ELISA and/or viral culture), five included suspected or confirmed cases, but reported 
outcomes only for those on which the diagnosis of CCHF was confirmed and seven 
studies included participants with a clinical or confirmed diagnosis of CCHF. The 
sample size of the included studies varied from 8 to 283 participants. Few studies 
reported the proportion of participants with co-morbidities (Additional file 2. 
Description of studies). A diagnosis of CCHF was confirmed by IgM and IgG 
antibodies in 18 studies and no information was provided in two studies; detection 
of viral antigens were used in 12 studies. Additional viral culture was used in two 
studies to confirm CCHF diagnosis (Additional file 2. Description of studies).  
 
Interventions: Except for one study, where ribavirin was administered intravenously 
[37], oral ribavirin was given within a median of three to seven days after onset of 
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symptoms. The dosage recommended by the World Health Organization (WHO) (30 
mg/kg as an initial loading dose, then 15 mg/kg every 6h for 4 days, and then 7.5 
mg/kg every 8h for 6 days) was used in 10 studies, different dosage was used in 
three studies and seven studies did not report the dosage of ribavirin used. Fourteen 
studies reported the use of supportive therapy and blood products and this 
information was not provided in six studies (Additional file 2. Description of studies). 
 
Outcomes: The primary outcome, mortality, was reported in 12 studies comparing 
ribavirin vs. no ribavirin treatment, in three studies comparing ribavirin treatment 
initiated in the first 5 days of onset or later, and in one study comparing ribavirin 
treatment with ribavirin and immunoglobulin. Adverse events (not described as 
serious or leading to treatment discontinuation) were reported in four studies and 
length of hospitalisation was reported in four studies. All other outcomes were not 
reported. 
 
Methodological assessment  
Figure 2 summarises methodological characteristics of all included studies. Further 
details are provided in the online material (Additional file 3. Risk of bias of included 
studies). Downs & Black [27] final score on the quality of the 21 included studies 
ranged from 0 to 16 with a median score of 4 (maximum possible score was 33). 
Scores for each of the five factors devised by Downs & Black [27] varied from 0 to 9 
for quality of reporting (maximum score = 11), 0 to 3 for external validity (maximum 
score = 3), 0 to 4 for internal validity bias (maximum score = 8), 0 to 3 for internal 
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validity confounding (maximum score = 6) and all studies received a 0 for power 
calculation (maximum score = 5). 
 
Effects of interventions 
Mortality rate: quantitative synthesis 
One RCT [33] and 11 observational studies [22, 35-43, 50] provided data on rate of 
mortality comparing ribavirin vs. no ribavirin treatment for CCHF (Figure 3). Ribavirin 
treatment was not superior to no ribavirin treatment to reduce the mortality rate in 
a single RCT (RR: 1.13, 95%CI: 0.29, 4.32, 136 participants). Ribavirin reduced 
mortality by 44% when compared to no ribavirin treatment in the pooled 
observational studies (RR: 0.56, 95%CI: 0.35, 0.90, 955 participants). Significant 
heterogeneity was observed for the pooled observational studies (Q=29.02, p=0.001, 
I2 = 65%). 
 
Mortality rate: qualitative synthesis 
One study, published in Persian, reported results of a randomised, single-blinded 
controlled study on which oral ribavirin with intravenous immunoglobulin was 
compared to oral ribavirin in only 60 CCHF patients [33]. Data is provided only for 
the 40 confirmed CCHF cases. Twelve patients received ribavirin plus 
immunoglobulin (intervention group) and 28 patients received only ribavirin (control 
group) during one week; patients were followed up for 8 weeks. Authors reported 
three deaths in each group.  
In an additional five studies [45, 46, 48, 51, 52] all participants received ribavirin 
treatment and rates of mortality were provided:  
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Ayten (2008) [48] described 63 adults (mean age: 46, SD: 16.9 years) from Eastern 
Turkey with a confirmed case of CCHF. Oral ribavirin was prescribed to 46 (73%) and 
a case-fatality ratio of 4.8% was reported, although it is unclear if this was only 
among those receiving ribavirin. 
 
Midilli (2007) [45] investigated the genetic diversity of the virus in 91 suspected 
cases of CCHF. In ten patients CCHF was confirmed using semi-nested polymerase 
chain reaction (PCR) following RT-PCR. Oral ribavirin was prescribed to all 10 
confirmed cases (dose not reported) and no deaths were reported. 
 
Sannikova (2007) [51] described a series of 283 adults (age not reported) from Russia 
with CCHF. Oral ribavirin was prescribed to all of them at a dose of 1000 to 1200 g 
per day for two days and no deaths were reported. 
 
Sharifi-Mood (2008) [46] described clinical and epidemiologic features of CCHF 
among 34 children and adolescents (mean age: 13.3, SD: 4.6 years) from a highly 
endemic region in Iran. Clinical manifestations were described as being similar to 
those in adults. The study reported a case-fatality ratio of 26.5% (9 of 34). 
 
Sheikh (2005) [52] described 135 suspected cases of CCHF, based on a five-year 
hospital based case series in the province of Balochistan in Pakistan. Eighty-three 
confirmed cases of CCHF were treated with oral ribavirin and the study reported a 
case-fatality ratio was 9.6% (8 of 83). 
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Adverse events  
One RCT [33] and three observational studies [37, 39, 43] provided data on adverse 
events comparing ribavirin vs. no ribavirin treatment to treat CCHF (Figure A of the 
online material). None of the adverse events were described as serious, or needed 
discontinuation of treatment and one of the studies reported no adverse events 
[40]. In the other three studies the observed adverse events were as follows. In 
Koksal 2009 [33] two patients developed serious anaemia and fatigue and these 
patients had to be hospitalised for a longer period of time. Cevik 2008 [37] was the 
only included study evaluating intravenous ribavirin in patients with severe CCHF; 
one patient developed an allergic maculopapular rash that was treated with 
antihistamines and two patients had nausea and vomiting due to intravenous 
ribavirin, and received symptomatic treatment. Ozkurt 2006 [43] described one case 
of mild hemolytic anemia due to ribavirin that recovered spontaneously after two 
days without withdrawing the drug. Ribavirin treatment did not cause more adverse 
events than no ribavirin treatment in a single RCT (RR: 5.62, 95%CI: 0.27, 114.83, 136 
participants), or in the pooled observational studies (RR: 8.12, 95%CI: 0.97, 67.59, 85 
participants, I2 = 0%). 
 
Length of hospital stay 
One RCT [33] and one observational study [36] provided information on the average 
length of hospital stay comparing patients using ribavirin vs. no ribavirin treatment 
to treat CCHF. Two other studies provided the p-value for the difference instead of 
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the average length of hospital stay in days [38, 43]. In order to merge the latter 
studies with the other two, we converted the data into the same effect size 
assuming a two-tailed p-value and independent, unmatched groups [29]. Pooled 
analysis can be seen in Figure 4. No difference was observed when those receiving 
ribavirin were compared to no ribavirin treatment in a single RCT (SMD: -0.21, 
95%CI: -0.55, 0.12, 136 participants), or in the pooled observational studies (SMD: -
0.60, 95%CI: -1.21, 0.00, 308 participants. Significant heterogeneity was observed for 
the pooled observational studies (Q=7.74, p=0.021, I2 = 74%). 
 
Antibody responses following exposure to CCHF virus 
One included study [44] aimed to detect antibodies against CCHF virus in healthcare 
workers in one of the largest referral tertiary-care community hospitals in Turkey. 
The sera from 75 healthcare workers were collected one month after the last 
admitted hospital case (October 2003), and tested for CCHF IgM and IgG by ELISA. 
Eighty three percent of the healthcare workers were at risk of exposure to the body 
fluids of patients, but only one was CCHF IgG positive. Authors reported that the high 
rate of compliance to the universal precautions protected healthcare workers 
against CCHF infection. No one in this study was given prophylactic ribavirin. 
 
Sub-group analysis 
Three observational studies [41, 47, 49] provided data comparing ribavirin treatment 
starting before or after 5 days of onset of disease. No statistically significant 
difference was observed between groups (RR: 0.31, 95%CI: 0.08 to 1.25, 344 
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participants). Significant heterogeneity was observed for the pooled observational 
studies (Q=13.52, p=0.001, I2 = 85%). 
 
GRADE assessment 
Table 1 provides an assessment of the effect estimates and the robustness of the 
data using the GRADE methodology. Ribavirin effects from observational data are of 
very low quality. 
 
Discussion and Conclusions 
Evidence that ribavirin has an effect on outcome in patients is limited. Trial data are 
confined to one recently conducted randomized, placebo-controlled trial. The 
confidence intervals are very wide, and so it is not possible to be confident about 
any effect from this data. Observational data suggest benefit, across the 11 studies, 
with confidence intervals that are significant. The point estimate suggests a 
potentially large effect, but the quality of the data is very low (see table 1), and the 
quality assessment shows a high risk of bias. Indeed, severity of illness is likely to 
confound the relationship: less severely ill patients survived long enough after 
admission to receive ribavirin, whereas the sicker patients may die sooner, and thus 
be less likely to receive ribavirin. Whilst studies are all consistent with benefit, we 
must guard against spurious precision from confounded association [53]. 
 
Also factors including include platelet count, white blood cell counts, INR and 
gastrointestinal hemorrhage have previously been shown to influence the outcome 
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of CCHF cases, and these have previously been described in prognostic scoring 
systems [39]. Unfortunately, the data from many of the trials reviewed here was 
limited and severity scores were not used uniformly, therefore this was difficult to 
assess. Severity criteria should also be taken into account in any future trials looking 
at ribavirin use in CCHF. 
 
Adverse effects are more common with ribavirin than with no treatment, but none 
were described as serious or required discontinuation of treatment. However, the 
number of studies and patients in whom this was reported was low. 
 
The mortality varies considerably between the case series and the trial. This may be 
a result of case mix (with some of the older case series detecting seriously ill people), 
supportive management that has been improving over time, or simply the trial 
effect, with falls in mortality in both treatment and control arms, as the trial 
environment generally improves care.  
 
Limitations of the current evidence 
Carrying out a randomised trial in this severe infectious disease is commendable and 
the trial reported follows good scientific principles. However, the strength of this 
review would have been greatly enhanced by a more complete reporting of data in 
the original papers. In particular, the single RCT did not report a procedure for 
randomisation, a method to guarantee an adequate allocation concealment and 
whether patients and/or healthcare workers were blinded to group assignment [33].  
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Furthermore, the final Downs & Black [27] quality score for the observational studies 
ranged from 0 to 16 with a median score of 4 (maximum possible score was 33), 
showing that even if carried out adequately, the study design has not been 
consistently reported.  
 
Applicability 
The patient population in the included trials was usually young adults, with one 
study reporting CCHF in children. Information concerning the risk factors of these 
patients and the mechanism of exposure to CCHF virus is scarce, as patient 
characteristics were rarely detailed. In addition, all included studies contributing 
data for this review were conducted in three countries (Iran, Pakistan, and Turkey), 
with many other countries reported as endemic areas [54] failing to report results of 
CCHF treatment or whether treatment with ribavirin is a current practice in these 
areas.  
 
The World Health Organization has approved ribavirin for use for CCHF and has 
added the drug to the essential drug list, mainly based on its in vitro effect 
(reference WHO Essential drugs submission) [55]. The drug is not cheap, therefore if 
indeed it is effective, it is important that its distribution is assured, that it is available 
immediately when an outbreak occurs, and health staff have clear procedures about 
when and how to use the drug. This will require substantive investment in purchase, 
distribution, and training in areas where health services are often fairly basic. A clear 
message from research evidence of the benefit of giving this drug, and the size of the 
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effect, will be of considerable help in justifying the investment required in ensuring 
all patients receive this drug promptly, and hence the need for further trials. 
 
Implications for practice  
Current research evidence is insufficient to be sure ribavirin is of benefit in this 
condition. Observational data are compatible with an effect, but are confounded and 
it is not possible to rely on this data alone. The estimates from randomised 
comparisons are compatible with both no effect and a substantive benefit.  
 
Implications for future research 
There is an urgent need to rapidly establish a multi-centred, simple mortality trial of 
ribavirin in CCHF.  
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Table 1: Summary of findings: ribavirin vs. no ribavirin for treating patients with CCHF 
(population: patients with CCHF; settings: hospital based; intervention: ribavirin) 
Outcomes Illustrative comparative risks* (95% CI) Relative 
effect 
(95% CI)
No of 
Participants
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments
Assumed risk Corresponding risk 
Control ribavirin 
Mortality (RCT) 
Follow-up: mean 8 
weeks 
56 per 1000 63 per 1000 
(16 to 242)
RR 1.13  
(0.29 to 
4.32) 
136 
(1 study) 
⊕⊕⊝⊝ 
low
1,2
 
 
Mortality 
(Observational 
studies) 
Follow-up: 1-12 
months 
254 per 1000 142 per 1000
(89 to 229) 
RR 0.56  
(0.35 to 
0.9) 
955 
(11 studies) 
⊕⊝⊝⊝ 
very 
low
3,4,5,6
 
 
Length of hospital 
stay (RCT) 
Days in hospital 
Follow-up: mean 8 
weeks 
The mean length of 
hospital stay (rct) in 
the control groups was
6.3 days 
The mean Length of 
hospital stay (RCT) in 
the intervention groups 
was 
0.21 standard 
deviations lower 
(0.55 lower to 0.12 
higher) 
 136 
(1 study) 
⊕⊝⊝⊝ 
very low
1,2
 
 
Length of hospital 
stay 
(Observational 
studies) 
days in hospital 
Follow-up: mean 4-
24 months 
The mean length of 
hospital stay 
(observational studies) 
in the control groups 
was 
6.4 days 
The mean Length of 
hospital stay 
(Observational studies) 
in the intervention 
groups was 
0.60 standard 
deviations lower 
(1.21 lower to 0 higher) 
 303 
(3 studies) 
⊕⊝⊝⊝ 
very 
low
3,5,6,7
 
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The 
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI).CI: Confidence interval; RR: Risk ratio 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
Assessment notes 
1
 No details of allocation concealment and method of randomisation was provided. Open label. 
2
 Wide confidence intervals. 
3
 Details of study design and population characteristics not provided in most studies. 
4
 Two studies (Alavi-Naimi 2006 and Nadeen 2003) were significantly more favourable to ribavirin than 
the other 9 included observational studies.  
5
 Although there was no significant lateral asymmetry on the funnel plot, and Egger’s regression was not 
significant (intercept: 0.829, 2-tailed p-value = 0.408), we cannot completely discard publication bias 
because all studies were observational and published onl in Iran, Pakistan and Turkey.  
6
 Most studies used historical controls and provided little or no information about how patients were 
selected, whether they represent the whole population in risk or characteristics of included patients. 
7
 One study (Cevik 2008) was significantly more favourable to ribavirin than the other 2 included 
observational studies.  
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Figures: 
Figure 1: Flow chart of studies included in this review 
Figure 2: Risk of bias assessment based on Downs & Black Checklist 
Figure 3: Rate of mortality in patients with CCHF: ribavirin vs. no ribavirin treatment 
Figure 4: Length of hospital stay in patients with CCHF: ribavirin vs. no ribavirin 
treatment 
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